Relevant coexpression of \textit{STMN1}, \textit{MELK} and \textit{FOXM1} in glioblastoma and review of the impact of \textit{STMN1} in cancer biology

Fernanda de Oliveira Serachi\textsuperscript{1}, Suely Kazue Nagahashi Marie\textsuperscript{1,II}, Sueli Mieko Oba-Shinjo\textsuperscript{I}

\textsuperscript{1}Universidade de Sao Paulo, Faculty of Medicine (FMUSP), Department of Neurology, Laboratory of Molecular and Cellular Biology (LIM 15), Sao Paulo, SP, Brazil
\textsuperscript{II}Universidade de Sao Paulo, Center for Studies of Cellular and Molecular Therapy (NAP-NETCEM-NUCEL), Sao Paulo, Brazil

OBJECTIVE: To analyze the associated expression of \textit{STMN1}, \textit{MELK} and \textit{FOXM1} in search of alternative drugable target in glioblastoma (GBM) and to review relevant functional roles of \textit{STMN1} in cancer biology.

METHOD: \textit{STMN1}, \textit{MELK} and \textit{FOXM1} expressions were studied by quantitative PCR and their coexpressions were analyzed in two independent glioblastoma cohorts. A review of articles in indexed journals that addressed the multiple functional aspects of \textit{STMN1} was conducted, focusing on the most recent reports discussing its role in cancer, in chemoresistance and in upstream pathways involving \textit{MELK} and \textit{FOXM1}.

RESULTS: Significant associated expressions of \textit{MELK} and \textit{FOXM1} were observed with \textit{STMN1} in GBM. Additionally, the literature review highlighted the relevance of \textit{STMN1} in cancer progression.

CONCLUSION: \textit{STMN1} is very important to induce events in cancer development and progression, as cellular proliferation, migration, and drug resistance. Therefore, \textit{STMN1} can be an important therapeutic target for a large number of human cancers. In glioblastoma, the most aggressive brain tumor, the \textit{MELK}/\textit{FOXM1}/\textit{STMN1} presented significant associated expressions, thus pointing \textit{MELK} and \textit{FOXM1} as alternative targets for therapy instead of \textit{STMN1}, which is highly expressed in normal brain tissue. Continuous functional research to understand the \textit{STMN1} signaling pathway is worthwhile to improve the therapeutic approaches in cancer.

KEYWORDS: Stathmin, cytoskeleton, microtubules, glioblastoma.

INTRODUCTION

Cell proliferation and migration are two relevant features in cancer biology determining tumor growth and invasion/metastasis. The subcellular cytoskeleton is essential to control these processes.\textsuperscript{1} This includes the microtubule dynamic behavior involving rapid switches between periods of polymerization (growth) and depolymerization (shrinkage) at the microtubule extremity (named dynamic instability).

Currently, several proteins are known to be related to microtubule interaction with tubulin, and participate in microtubule dynamics. The stathmin (STMN) family members are among those proteins that inhibit microtubule polymerization. Four members of evolutionarily conserved cytosolic proteins compose this family, namely \textit{STMN1} to 4. \textit{STMN1} and \textit{STMN3} are ubiquitously expressed in different cells, while \textit{STMN2} and \textit{STMN4} are more restricted to the nervous system.\textsuperscript{2} These proteins share up to 70\% of sequence homology in a highly conserved C-terminus within the tubulin-binding stathmin-like domain, and in the N-terminus region containing the phosphorylation sites, which also dictates their cellular localization.\textsuperscript{3,4}

\textit{STMN1} is also known as Oncoprotein 18 (Op 18); it is an important microtubule dynamics regulator involved in cell proliferation, differentiation, cell cycle progression...
STMN1 has been described as associated to a wide range of malignancies and is a target for alternative therapy in cancer treatment. STMN2, also known as the superior cervical ganglion-10 protein (SCG10), has been reported as a neuron-specific growth-associated phosphoprotein, abundant in the growth cone of neurons. In particular, STMN2 is described as a neuronal marker at an early stage of neural development, playing a regulatory role in the control of neuronal differentiation. Previous studies have also described its role in osteogenesis. In liver tumorigenesis, it has been described as a target of β-catenin/TCF-mediated transcription in the Wnt dependent regulation of microtubule dynamics in hepatoma cells. Moreover, STMN2 plays a role in promoting the invasive potential of gastric cancer cells.

STMN3, also known as SCLIP, is involved in the development of the central nervous system, including axonal branching and dendritic differentiation of Purkinje cells. STMN3 is highly expressed in glialma samples, and has been associated to migration and invasion of glioma cells. Additionally, STMN3 has been described as a modulator of the sensitivity of ovarian cancer cells to microtubule-targeting drugs by preventing the formation of the spindle and consequently promoting mitosis arrest.

STMN4, also known as RB3, presents two splice variants, RB3' and RB3''. STMN4 has a putative role in neuronal morphogenesis and plasticity.

Among the members of the stathmin family, STMN1 is the most studied member, and cumulative evidence singles out STMN1 as a candidate target for cancer therapy. However, STMN1 can hardly become an eligible drug for brain tumors, as its expression is high in brain tissue, and consequently undesirable side effects would be expected. Therefore, the search for more suitable up or downstream targets in the STMN1 signaling pathway is an alternative strategy. On this rationale, we previously linked MELK upstream to STMN1 in glioma cells, and have also demonstrated the importance of MELK in astrocytoma progression, mainly in GBM. More recently, AKT/FOXM1/STMN1 pathway has been reported to confer multidrug resistance phenotype in non-small cell lung cancer.

FOXM1 is a transcription factor of the forkhead family that plays critical roles in cell cycle progression and cell fate decision.

In the present work, we analyzed the STMN1, MELK and FOXM1 expression levels in our GBM cohort, and validated our results in an expanded independent public cohort in silico. To highlight the relevance of this pathway in cancer biology, we also present a review focused on the role of STMN1 in tumor progression promoting proliferation and migration through regulation of microtubule dynamics.

### MATERIALS AND METHODS

#### Analysis of Cases and Gene Expression

Eighty-seven astrocytomas grade IV or GBM and 22 non-neoplastic (NN) brain anonymized tissues from epilepsy patients subjected to temporal lobectomy were obtained during therapeutic surgery from patients treated by the Neurosurgery Group of the Department of Neurology at Hospital das Clínicas of the Faculdade de Medicina da Universidade de São Paulo. Written informed consents were obtained from all patients in accordance with ethical guidelines. This project was approved by the Ethic Committee of Faculdade de Medicina da Universidade de Sao Paulo (case # 0263/07).

Samples were immediately snap-frozen in liquid nitrogen and necrotic and non-neoplastic areas were removed by microdissection from the tumoral blocks prior to RNA extraction. Total RNA extraction, reverse transcription and qRT-PCR (Sybr Green approach) were performed as previously described. Quantitative data were normalized using the geometric mean of three reference genes suitable for the analysis: hypoxanthine phosphoribosyltransferase (HPRT), glucuronidase beta (GUSB) and TATA box-binding protein (TBP), as previously demonstrated by our group. Primers of housekeeping genes, STMN1 and MELK are described in our previous report.

Primers for FOXM1 were synthesized by (Integrated DNA Technologies, IDT, Coralville, IA) as follows (5′ to 3′): FOXM1 F: GAAGAACTCGCTTATGCTCT, FOXM1 R: TCAAGTAGCGGTTGGCACTG. All reactions were performed in duplicates and and the 2^−ΔCt method was applied to calculate gene expression levels, where ΔCt = [Ct target gene] - [geometric mean Ct of reference genes] and Ct is the cycle threshold. The median values of gene expression were used to divide samples with high and low expression.

#### Analysis of The Cancer Genome Atlas (TCGA) GBM gene expression database

STMN1, MELK and FOXM1 gene expression levels were analyzed in an independent cohort at the cBio Portal for Cancer Genomics database (http://www.cbioportal.org). RNAseq data set of 154 cases of GBM was used to assess coexpression analysis of mRNA levels (z-score, RNA Seq V2 RSEM).

#### Statistical analyses

Mann Whitney tests were performed to compare STMN1, MELK and FOXM1 expression levels between GBM and NN samples. Correlations between gene expression values in different groups of tumors were assessed using the Spearman-rho correlation tests (non-parametric test).
Literature review focused in STMN1

A literature search was conducted in the PubMed database using the following terms: “stathmin”, “cancer”. Only articles in English were selected, with a search ending in September 2017. We selected reviews and articles that described STMN1 and cancer. We focused specially in the most recent data of STMN1 role in cancer treatment and chemoresistance.

■ RESULTS

We aimed to analyze the association of STMN1, MELK and FOXM1 in two independent cohorts of GBM. Initially, we analyzed STMN1, MELK and FOXM1 expression levels in 87 GBM samples compared to 22 non-neoplastic (NN) brain samples in our case database (Figure 1A, B and C).

Coexpression analyses were significantly positive for STMN1 and MELK, STMN1 and FOXM1 and MELK and FOXM1 (Figure 1D, E and F). Our results were validated in a larger independent public database of TCGA corroborating the tight association among MELK, FOXM1 and STMN1 (Figure 1G, H and I).

Additionally, we divided the GBM cases of our cohort in low (44 cases) and high (43 cases) STMN1 expression. In the first group, there were 11 cases (25%) that presented high FOXM1 expression, while in the second group there were 32 cases (73%) with high FOXM1 expression (Figure 2). Our data indicate that overexpression of STMN1 correlates to an overexpression of FOXM1.

■ DISCUSSION

Altogether, our data demonstrate that MELK and FOXM1 expressions are significantly associated to STMN1 expression, pointing them as promising alternative targets in the STMN1 signaling pathway for glioma therapy.

A schematic illustration of the signaling pathway involving STMN1, MELK and FOXM1 is proposed in Figure 3, implementing the interaction network recently published.19 STMN1 plays a central role in the regulation of cell cycle, proliferation, epithelial mesenchymal transition and chemoresistance, crucial processes in cancer progression. The details of these STMN1 roles are reviewed and presented below.

Figure 1. STMN1, MELK and FOXM1 expression levels in glioblastoma (GBM) and non-neoplastic brain tissue samples (NN). A, B, C: Box and whiskers plots of STMN1, MELK and FOXM1 gene expressions in GBM and NN groups analyzed by real time PCR. The top and bottom of boxes represent the first and third quartiles, respectively, and the lines in the middle the median expression in the groups. The error bars show the range of 5-95th percentiles (whiskers). D, E, F: Coexpressions between STMN1 and MELK, STMN1 and FOXM1 and MELK and FOXM1 expression levels in our GBM series (Spearman-rho test). G, H, I: Coexpressions between STMN1 and MELK, STMN1 and FOXM1 and FOXM1 and MELK expression levels analyzed in RNAseq data of 157 cases from a GBM-TCGA cohort by z-Score (of RSEM).
Figure 2. STMN1 and FOXM1 expression analysis of our GBM cohort. We divided the GBM samples according to STMN1 expression (low and high, based on median gene expression values). The horizontal bars represent the median expression of each group. Red dots represent cases with high FOXM1 expression levels (cases above median of FOXM1 expression level).

STMN1 and microtubule dynamics

Tight regulation of cytoskeletal microtubule dynamics in living cells is essential for many cellular functions. Microtubules are a network of filaments comprising heterodimer α/β-tubulin subunits that play a key role during cell events such as proliferation, migration and differentiation. The dynamic reorganization of microtubules in cells is regulated by proteins that promote their assembly (stabilizers) or disassembly (destabilizers). Microtubules (dis)assembly is partially determined by the concentration of free tubulin heterodimers in the cytoplasm, where it determines the growth rate of microtubule by incorporation of tubulin at its ends. STMN1 is one of the most prominent and rapid microtubule regulators in response to cell needs. STMN1 downregulation increases the concentration of microtubule polymers and decreases the concentration of free tubulin heterodimers.23

STMN1 (de)phosphorylation and cell cycle

The dynamic regulation of the tubulin assembly by STMN1 is performed by its four extremely conserved phosphorylation sites within the N-terminal domain: Ser16, Ser25, Ser38 and Ser63.24,25 The dephosphorylated (active) STMN1 promotes the depolymerization of microtubules by sequestering tubulin heterodimers into a ternary complex T2S where one STMN1 molecule interacts with two molecules of α,β-tubulin through the stathmin-like domain.26 On the other hand, the phosphorylated (inactive) STMN1 impacts negatively on STMN-tubulin association, and therefore promotes microtubule stabilization and formation of mitotic spindle.27 This post-translational phosphorylation of STMN1 by multiple kinases is largely dependent on specific stimulus especially during cell cycle progression, and migration.28

In mitotic cells, sequential phosphorylation of the four residues of STMN1 blocks tubulin binding to T2S and terminates depolymerization activity, consequently allowing the spindle formation.29 Initially, a moderate STMN1 inactivation is achieved by Ser25 and Ser38 phosphorylation by MAPK and p34<sup>cdk2</sup> during G1/S phase. Next, for the metaphase initiation, these two residues are phosphorylated by CDK1, a master regulator of M phase progression, and also by CDK2 and CDK5.30,31 STMN1 total inactivation occurs by sequential phosphorylation of Ser16 and Ser63 residues.32,33 by protein kinase A (PKA),24,34 Aurora B kinase,35 p65PAK,36 or Ca<sup>2+</sup>/calmodulin-dependent kinases isoforms CaMKII and IV at the final step of M phase.37,38 Such a condition allows the mitotic spindle to be properly organized.32,33 When chromosome segregation is completed, the spindle must be disassembled to allow proper exit from mitosis, and enter to anaphase and telophase.40 The microtubule-depolymerizing
activity of STMN1 is restored by dephosphorylation to disassemble the mitotic spindle. At this point, different serine/threonine protein phosphatases, as protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A) and protein phosphatase 2B (PP2B), dephosphorylate STMN1.41,42

Additionally, STMN1 phosphorylation at Ser28 and Ser38 residues is also mediated by c-Jun N-terminal kinase (JNK).43,44 The JNKs are stress-activated serine/threonine kinases that regulate both cell death and cell proliferation, and they are also regulators of critical processes such as inflammation and metabolism. c-JUN overexpression also stimulates STMN1 transcription via direct activation of its promoter by the activating transcription factor (ATF)-like or by indirect activation of the E2F activity.45 Extracellular signal-regulated kinases (ERK), also known as mitogen-activated kinase (MAPK) act as an integration point for multiple biochemical signals, and also phosphorylate STMN1 of unknown function, that is frequently up-regulated in transformed cells. Stimulation of various cell surface receptors results in extensive phosphorylation of Op18 and this protein has, therefore, previously been implicated in intracellular signaling. In the present study, by expression of specific Op18 cDNA mutant constructs and phosphopeptide mapping, we have identified in vivo phosphorylation sites. In conjunction with in vitro phosphorylation experiments, using purified wild-type and mutant Op18 proteins in combination with a series of kinases, these results have identified two distinct proline-directed kinase families that phosphorylate Op18 with overlapping but distinct site preference. These two kinase families, mitogen activated protein (MAP)4 Also in the MAPK cascade, apoptosis signal-regulating kinase (ASK1) activates the JNK and p38 MAPK cascades through STMN1 phosphorylation and ASK1 is involved in a broad range of activities including cell differentiation and stress-induced apoptosis.46-48 Moreover, ribosomal protein S6 kinase A3 (RPS6KA3, RSK2) can reduce microtubule depolymerization by phosphorylation of STMN1 specifically at Ser16 residue.49

Additionally, peptide hormones as gonadotropin-releasing hormone (LHRH) secreted from hypothalamic neurons, regulators of LH and FSH synthesis and release, have also been described to induce STMN1 phosphorylation in a PKC-dependent pathway.50 More recently, thyroid hormone receptor (THR) has been reported as a transcription regulator of STMN1 in hepatocellular carcinoma. Thyroxine (T3) binds to nuclear TRHs to exert numerous physiological processes, including onogenesis, cell growth, cellular differentiation and metabolism. Clinical and experimental observations suggest that T3 might regulate microtubule network assembly through repression of STMN1 expression.51

In addition to hormones and growth factors, ion channels can also activate STMN1. Activation of ion channels initiate a Ca2+ response in parallel with activation of several protein kinase families, particularly Ca2+/Calmodulin-dependent protein kinase type Gr which is mainly expressed at high levels in neural cells and CD4-positive T lymphocytes. And, as consequence STMN1 is phosphorylated.52,53

Therefore, STMN1 is able to integrate multiple extracellular inputs through hormone peptides, ion channels, and growth factor receptors to intracellular molecular networks, regulating multiple cellular activities and signaling pathways.

STMN1 and cell migration

Cell migration is a complex cellular behavior that results from the coordinated changes in the regulation of microtubule dynamics.52 Therefore, STMN1, a master microtubule regulator, is also involved in cell migration, with crucial role in cytoskeletal rearrangements for formation and dispersal of adhesion sites between cells and extracellular matrix. Intrinsically, STMN1 is involved in extension and retraction of leading edges which depend on polymerization of actin microfilaments, and microtubule assembly (stability) and disassembly (instability).53,54

Microtubules may participate in cell migration in a Rac1- and p21-activated kinase-dependent manner. In the advancing cell edge of the migrating cells, there is a Rac1 mediated microtubule net growth dependent on Pak kinase activity. Pak1 can directly phosphorylate STMN1 at S16 residue, in EGF-stimulated cells. This leads to downregulation of the STMN1 inhibitory activity on bulk tubulin polymerization with consequent microtubule growth.55

Moreover, STMN1 may interact with p27 and Cdk2/Cdk5, leading to enhanced protein phosphorylation and consequent tubulin stabilization and inhibition of cell migration.56

Another recent study has demonstrated that STMN1 phosphorylation at Ser25 and Ser38 is required to maintain the migration properties of breast cancer cells through interaction with glucose-regulated protein of molecular mass 78 (GRP78). Furthermore, this interaction is regulated by MEK kinase-dependent phosphorylation of STMN1, which has an important role in cell proliferation, differentiation, migration and invasion of breast cancer cells with impact on tumor recurrence and metastasis.57 Similarly, STMN1 was described as playing a fundamental role in neuroblastoma cells by regulating the invasion and transendothelial migration by RhoA/ROCK signaling, in a microtubule-independent manner.58 Association of STMN1 expression with metastasis has also been reported in other types of tumor, indicating STMN1 as a molecular biomarker for the risk of metastasis.5

STMN1 and cancer

STMN1 modifications have been frequently reported in cancer. In 2010, Jeon et al. first reported positive correlation of STMN1 overexpression with lymph node metastasis,
migration foci and vascular invasion, with negative impact in recurrence free survival of diffuse type of gastric carcinoma. The same group demonstrated the oncogenic role of STMN1 by the decrease of proliferation rate, migration and invasion of gastric cancer cells in vitro through STMN1 inhibition. \(^{59}\) Henceforth, STMN1 has been considered as a mitotic regulator oncoprotein that modulates microtubule stability. \(^{60}\)

STMN1 expression is also upregulated in various human malignancies, including colorectal, \(^{61}\) ovarian, \(^{62,63}\) hepatocellular, \(^{64,65}\) gastric, \(^{66,67}\) cutaneous, \(^{68}\) prostate, \(^{69}\) breast, \(^{70,71}\) cervical, \(^{72}\) lung, \(^{73-75}\) bladder, \(^{76}\) colorectal, \(^{77}\) pancreas, \(^{78,79}\) nasopharyngeal, \(^{80}\) esophageal, \(^{81,82}\) oral squamous cell, \(^{83}\) gallbladder, \(^{84}\) endometrial cancer, \(^{85,86}\) choleangiocarcinoma, \(^{87}\) GBM, \(^{17}\) medulloblastoma, \(^{88,89}\) meningomas, \(^{90,91}\) and acute leukemia. \(^{92}\) Upregulated STMN1 expression and/or activity (phosphorylation status) have been correlated with tumor grade, tumor progression, invasion/metastasis, poor survival and drug resistance in several types of malignancies firstly identified as the downstream target of many signal transduction pathways. Several studies then indicated that stathmin is overexpressed in many types of human malignancies, thus deserving the name of Oncoprotein 18 (Op18), \(^{5,28}\) highlighting the central role of STMN1 in tumor onset and progression. Accordingly, cumulative evidences have demonstrated reduction of important features of tumor, such as cell proliferation, motility, and metastasis by STMN1 downregulation.

In cancer, the most common and studied mechanism of STMN1 activation is mediated by phosphorylation by several intracellular signaling kinases, as mentioned above, but it can also be mediated by protein sequestration. The p27 \(^{93}\), a cyclin-dependent kinase (CDK) inhibitor, \(^{55,93,94}\) and STAT3, a transcription factor signal transducer and activator transcription 3, \(^{95,96}\) are both able to bind to STMN1, and consequently preventing its ability to sequester free tubulin heterodimers. FOXM1 is another transcription factor able to activate STMN1, as demonstrated recently in non-small cell lung cancer. \(^{19}\) Recently, we identified STMN1 as one of the proteins downstream the maternal embryonic leucine zipper kinase (MElk) pathway in GBM cell lines. \(^{17}\) Similar to STMN1, MElk is involved in tumor cell cycle, proliferation and differentiation in several human cancers. \(^{97}\) MElk silencing has led to the decrease of STMN1 expression. \(^{17}\) And, MElk directly binds to FOXM1 and regulates its phosphorylation, \(^{99}\) and consequently FOXM1 modulates STMN1 expression. \(^{17}\)

On the other hand, STMN1 downregulation can be modulated by \(TP53\), a transcription factor that represses \(STMN1\) transcription and regulates cell cycle arrest at the G2/M and G1/S checkpoints. \(^{99,100}\) There are cumulative evidences that STMN1 is the key downstream target of p53, mainly in cells harboring mutant p53 protein, as in hepatocellular carcinoma patients. And such condition is associated to a poorer prognosis. \(^{101}\) Corroborating these observations, \(STMN1\) inhibition in cancer cells harboring \(TP53\) mutation has decreased cell proliferation and viability; increased apoptosis and suppressed tumorigenicity, suggesting that STMN1 is required for the survival of p53-mutant cells. \(^{102-105}\) Recently, it was suggested that overexpressed STMN1 interacts with p53 and contributes to the gain-of-function of p53. \(^{105}\) Altogether, these data suggest that targeting STMN1 may be an! interesting approach to treat different types of cancers with aberrant p53 function.

Additionally, small non-coding RNAs, micro-RNAs (miRNAs) also modulate STMN1 expression. STMN1 is negatively regulated by the oncogene miR-221 during epithelial-mesenchymal transition (EMT) in bladder cancer cells \(^{106}\) and by miR-34a in osteosarcoma. \(^{107}\) Downregulation of miR-223 has been described to increase STMN1 expression in liver cancer, stimulating tumor cell growth and mobility. \(^{108}\)

These cumulative evidences corroborating the oncoprotein properties of STMN1 turn it a potential therapeutic target.

**STMN1 as potential therapeutic target**

STMN1 expression may be modulated interfering in the several mechanisms enumerated above, and also through \(\text{Nf-κB}\) in pancreatic cancer, where \(STMN1\) silencing reduced cell viability and promoted cell cycle arrest at G2/M phase. \(^{78}\) Or, by inhibiting of \(\text{HIF-1α}\) and \(\text{VEGF}\) mRNA levels through the decrease of AKT phosphorylation in the P38K/AKT/mTOR signaling pathway, as in ovarian cancer. \(^{109}\)

Of note, STMN1 modulation may be of interest to approach multidrug resistance. Chemosensitivity of several solid cancers, including non-small cell lung (NSCLC), esophageal, breast, gastric, endometrial, bladder, retinoblastoma, glioma, osteosarcoma and colorectal cancers has been related to overexpression of \(STMN1\). This association was described especially for microtubule-destabilizing drugs, such as taxol, paclitaxel and docetaxel, but also for platinum, temozolamide, doxorubicin, arsenic acid, gefitinib and zoledronic acid. \(^{110-112}\) More recently, upregulation of \(STMN1\) expression by FOXM1 has been described in NSCLC. \(STMN1\) overexpression was related to EMT and conferred multidrug tyrosine kinase inhibitors (TKIs) resistance on these cells. Mechanistically TKIs, the first group of target-based compounds used as therapy for large numbers of cancer, activate AKT/FOXM1/STMN1 pathway that has conferred multidrug resistance phenotype. \(^{19}\)

**SUMMARY**

Altogether, the results reviewed above suggest that expression of the STMN1 is very important to induce events in cancer development and progression, as cellular proliferation, migration, and drug resistance. Therefore, STMN1...
STMN1 and cancer
Serachi FO

Em GBM, o tumor cerebral mais agressivo, MELK/FOXM1/STMN1 apresentaram significativa associação em suas expressões gênicas, indicando, portanto, MELK e FOXM1 como alvos alternativos para terapia em substituição ao STMN1, que apresenta alta expressão no tecido cerebral normal. Perseverar nos estudos funcionais para o entendimento da via de sinalização do STMN1 é relevante para melhorar os esquemas terapêuticos para câncer.

PALAVRAS-CHAVE: Stathmin, citoesqueleto, microtúbulos, glioblastoma

■ ACKNOWLEDGEMENTS

We thank the Sao Paulo Research Foundation (FAPESP), grants 2013/02162-8 and 2015/03614-5, Conselho Nacional de Pesquisa (CNPq), Fundação Faculdade de Medicina (FFM) and Faculdade de Medicina da USP (FMUSP) for financial support.

■ AUTHOR CONTRIBUTION

F.O.S, S.K.N.M. and S.M.O.S. conceived and wrote the manuscript.

■ CONFLICT OF INTEREST

All the authors declare that have no conflicts of interest with respect to this manuscript.

COEXPRESSÃO RELEVANTE DE STMN1, MELK E FOXM1 EM GлиОBLASTOMA E REVISÃO DO IMPACTO DE STMN1 NA BIOLOGIA DO CÂNCER

OBJETIVO: Analisar as expressões associadas de STMN1, MELK e FOXM1 na procura de alvos alternativos de tratamento em glioblastoma (GBM) e revisar os papeis funcionais relevantes de STMN1 na biologia do câncer.

MÉTODO: As expressões de STMN1, MELK e FOXM1 foram estudadas por PCR quantitativa e suas coexpressões foram analisadas em dois coortes independentes de GBM. A revisão dos artigos publicados em revistas indexadas foi conduzida focando-se nos estudos mais recentes discutindo o seu papel em câncer, quimiorresistência e vias de sinalização envolvendo MELK e FOXM1.

RESULTADOS: Observou-se expressões associadas significantes de MELK e FOXM1 com STMN1. Adicionalmente, a revisão da literatura salientou a relevância do STMN1 na progressão do câncer.

CONCLUSÃO: STMN1 é muito importante nos eventos relacionados ao desenvolvimento e progressão do câncer, como proliferação celular, migração e resistência ao tratamento. Desta forma, STMN1 pode ser um forte alvo terapêutico em um grande número de cânceres humanos.

REFERENCES

1. Gardner MK, Zanic M, Howard JW. Microtubule catastrophe and rescue. Curr Opin Cell Biol. 2013;25(1):1-9. DOI:10.1016/j.ceb.2012.09.006
2. Bièche I, Mauruer A, Laurendeau I, Lachkar S, Spano AJ, Frankfurter A, et al. Expression of stathmin family genes in human tissues: Non-neural-restricted expression for SCLIP. Genomics. 2003;81(4):400-10. DOI:10.1016/S0888-7543(03)00031-4
3. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr. Opin. Cell Biol. 2002;14(1):18-24. DOI:10.1016/S0955-0674(01)00289-7
4. Lin X, Liao Y, Chen X, Long D, Yu T, Shen F. Regulation of Oncoprotein 18/stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells. Cancer Biother Radiopharm. 2016;31(2):37-43. DOI:10.1089/cbr.2015.1921
5. Biauxxe R, Hua L, Wenlong G, Shuanying Y. Overexpression of stathmin promotes metastasis and growth of malignant solid tumors: a system review and meta-analysis. Oncotarget. 2016;7(48):78994-9007. DOI:10.18632/oncotarget.12982
6. Grenningloh G, Soehman S, Bondallaz P, Ruchti E, Cadas H. Role of the microtubule destabilizing proteins SCl and stathmin in neuronal growth. J Neurobiol. 2004;50(1):60-9. DOI:10.1002/neu.10279
7. Chiellini C, Grenningloh G, Cochet O, Scheideler M, Trajanoski Z, Ailhaud G, et al. Stathmin-like 2, a developmentally-associated neuronal marker, is expressed and modulated during osteogenesis of human mesenchymal stem cells. Biochem Biophys Res Commun. 2008;374(1):64-8. DOI:10.1016/j.bbrc.2008.06.121
8. Lee HS, Dinh VC, Park M-H, Yang S-J, Lee JJ, Kim DM, et al. STMN2 is a novel target of beta-catenin/TCF-mediated transcription in human hepatoma cells. Biochem Biophys Res Commun. 2006;345(3):1059-67. DOI:10.1016/j.bbrc.2006.05.017
9. Guo Q, Su N, Zhang J, Li X, Miao Z, Wang G, et al. PAK4 kinase-mediated SClG10 phosphorylation involved in gastric cancer metastasis. Oncogene. 2014;33(25):3277-87. DOI:10.1038/onc.2013.296
10. Poullin FE, Sobel A. The “SCG10-Like Protein” SClIP is a novel regulator of axonal branching in hippocampal neurons, unlike SCG10. Mol Cell Neurosci. 2007;34(2):137–46. DOI:10.1016/j.mcn.2006.10.012
11. Poullin FE, Chaouvin S, Wehrle R, Desclaux M, Mallet J, Vojdani G, et al. SClIP is crucial for the formation and development of the Purkinje cell dendritic arbor. J Neurosci. 2008;28(29):7387-98. DOI:10.1523/JNEUROSCI.1942-08.2008
12. Zhang Y, Ni S, Huang B, Wang L, Zhang X, Li X, et al. Overexpression of SClIP promotes growth and motility in glioblastoma cells. Cancer Biol Ther. 2015;16(1):97-105. DOI:10.4161/15384047.2014.987037
13. Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, et al. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to chemotherapy. Cancer Biol Ther. 2015;16(1):97-105. DOI:10.4161/15384047.2014.987037
14. Ouzon S, Mauruer A, Sobel A. The stathmin family molecule and biological characterization of novel mammalian proteins expressed in the nervous system. Eur J Biochem. 1997;248:794-806. DOI:10.1111/j.1432-1033.1997.tb00794.x
15. Beilharz EJ, Zhukovsky E, Lanahan AA, Worley PF, Nikolich K, Goodman LJ. Neuronal activity induction of the stathmin-like gene RB3 in the rat hippocampus: possible role in neuronal plasticity. J Neurosci. 1998;18(23):9780-9.

16. Marklund U, Larsson N, Brattsand G, Osterman O, Chatila TA, Gullberg M. Modulation of the stathmin-like microtubule destabilizing activity of RB3, a neuron-specific member of the SGG10 family, by its N-terminal domain. J Biol Chem. 2004;279(22):23041-21. DOI:10.1074/jbc.M313693200

17. Marie SK, Oba-Shinjo SM, da Silva R, Gimenez M, Nunes Reis G, Tassan JP et al. Stathmin involvement in the maternal embryonic leucine zipper kinase pathway in glioblastoma. Proteome Sci. 2016;14:6. DOI:10.1186/s12953-016-0094-9

18. Marie SK, Okaamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T et al. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer. 2008;122(4):807-15. DOI:10.1002/ijc.23189

19. Li M, Yang J, Zhou W, Ren Y, Wang X, Chen H et al. Activation of an AKT/FOX/M/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017;117(7):974-83. DOI:10.1038/jbc.2017.292

20. Valente V, Teixeira SA, Neder L, Dresnurz G, Bross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the eBioPortal. Sci. Signal. 2013;6(269):pl1. DOI:10.1126/scisignal.2040888

21. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al. TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2015;163(3):780-94. DOI:10.1016/j.cell.2015.06.033

22. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al. TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2015;163(3):780-94. DOI:10.1016/j.cell.2015.06.033

23. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR et al. TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2015;163(3):780-94. DOI:10.1016/j.cell.2015.06.033

24. Belmont LD, Mitchison TJ. Identification of a protein that interacts with cdc15, a cell cycle checkpoint kinase that controls nuclear division. J Biol Chem. 1992;267(21):16078-83. DOI:10.1074/jbc.267.21.16078

25. Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 2011;15(11):1249-59. DOI:10.1517/14728222.2011.620951

26. Benes V, Leblond PT, Michelson TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell. 1996;83(4):623-33. DOI:10.1016/S0092-8674(00)81037-5

27. Honmappa S, Jahnke W, Seelig J, Steinmetz MO. Control of intrinsically disordered stathmin by multiprotein complex formation. J Biol Chem. 2016;291(23):12678-88. DOI:10.1074/jbc.M115624200

28. Beilharz EJ, Zhukovsky E, Lanahan AA, Worley PF, Nikolich K, Goodman LJ. Neuronal activity induction of the stathmin-like gene RB3 in the rat hippocampus: possible role in neuronal plasticity. J Neurosci. 1998;18(23):9780-9. DOI:10.1074/jpc.2017.292

29. Strahler JR, Lamb BJ, Ungar DR, Fox DA, Hanash SM. Cell cycle progression is associated with distinct patterns of phosphorylation of Op18. Biochem Biophys Res Commun. 1992;185(1):230-8. DOI:10.1016/0006-291X(92)80075-1

30. Brattsand G, Marklund M, Nylander K, Roos G, Gullberg M. Cell-cycle-regulated phosphorylation of stathmin-like protein on serine 18. J Biol Chem. 1994;269(23):23041-21. DOI:10.1074/jbc.269.23.23041

31. Li M, Yang J, Zhou W, Ren Y, Wang X, Chen H et al. Activation of an AKT/FOX/M/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017;117(7):974-83. DOI:10.1038/jbc.2017.292

32. Larsson N, Marklund M, Grodic H, Brattsand G, Gullberg M. Control of microtubule dynamics by stathmin-like protein on serine 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol. 1997;17(9):5530-9. DOI:10.1128/MCB.17.9.5530

33. Andersen SS, Ashford AJ, Tournebize R, Gavet O, Sopel A, Hyman AA, et al. Mitotic chromatin regulates phosphorylation of Stathmin/Op18. Nature. 1997;389(6651):640-3. DOI:10.1038/39382

34. Schubart UK, Alago W, Donaff A. Properties of a protein, a novel cAMP-dependent protein kinase substrate protein purified from bovine brain. J Biol Chem. 1987;262(24):11871-7.

35. Gadea BB, Ruderman JV. Aurora B is required for mitotic chromatin-induced phosphorylation of Op18/Stathmin. Proc Natl Acad Sci U S A. 2006;103(12):4493-8. DOI:10.1073/pnas.0607020103

36. Daub H, Gevaert K, Vandekerckhove J, Sopel A, Hall A, Rac/Cdc42 and p65/MAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J Biol Chem. 2001;276(3):1677-80. DOI:10.1074/jbc.000635200

37. Marklund U, Larson N, Brattsand G, Osterman O, Chatila TA, Gullberg M. Serine 16 of opontin 18 is a major cytosolic target for the Ca2+/calmodulin-dependent kinase Gc. Eur J Biochem. 1994;225(1):53-60. DOI:10.1111/j.1432-1033.1994.00053.x

38. le Gouvello S, Manceau V, Sopel A. Serine 16 of stathmin as a cytosolic target for the Ca2+/calmodulin-dependent kinase II after CD2 triggering of human T lymphocytes. J Immunol. 1998;161(3):1113-22

39. Honmappa S, Jahnke W, Seelig J, Steinmetz MO. Control of intrinsically disordered stathmin by multiprotein complex formation. J Biol Chem. 2016;291(23):12678-88. DOI:10.1074/jbc.M115624200

40. Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of stathmin on cell cycle-regulated phosphorylation of stathmin. Biochem J. 1996;320(2):345–54. DOI:10.1042/BJ19960325

41. Yeap YY, Nag IH, Badrian B, Nguyen T-V, Yip YY, Dhillon AS, et al. c-Jun N-terminal kinase/c-Jun inhibits fibroblast proliferation by negatively regulating the level of stathmin/Op18. Biochem J. 2010;430(2):345–54. DOI:10.1042/BJ20100425

42. Yip YY, Yeap YYC, Bogoyevitch MA, Ng DC. Differences in c-Jun N-terminal kinase recognition and phosphorylation of closely related stathmin- family members. Biochem. Biophys Res Commun. 2014;446(1):248-54. DOI:10.1016/j.bbrc.2014.02.101

43. Kinoshita I, Leamer V, Katabami M, Manzano RG, Dent P, Sabichi A et al. Identification of c-Jun responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for c-Jun-mediated anchorage-independent growth. Oncogene. 2004;23(2):271-80. DOI:10.1038/sj.onc.1207371

44. Schubart UK, Alago W, Donaff A. Properties of a protein, a novel cAMP-dependent protein kinase substrate protein purified from bovine brain. J Biol Chem. 1987;262(24):11871-7.

45. Anderton J, Silvers M, Young CI, Hummer J, Young CI, Hummer J et al. Identification of c-Jun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for c-Jun-mediated anchorage-independent growth. Oncogene. 2004;23(2):271-80. DOI:10.1038/sj.onc.1207371
68. Li X, Wang L, Li T, You B, Shan Y, Shi S, et al. STMN1 overexpression correlates with biological behavior in human cutaneous squamous cell carcinoma. Pathol Res Pract. 2015;211(11):816-23. DOI:10.1016/j.prp.2015.07.009

69. Sabherwal N, Mahajan N, Helseth DL, Gassmann M, Shi H, Zhang M. PDE5 downregulates stathmin expression in prostate cancer. Int J Oncol. 2012;40(6):1809-99. DOI:10.3892/ijo.2012.1392

70. Baquerio MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, et al. Stathmin expression and its relationship to microtubule- associated protein tau and outcome in breast cancer. Cancer. 2012;118(19):4660-9. DOI:10.1002/cncr.272453

71. Procházková I, Lenóıı J, Fuˇcıková A, Dresler J, Čapková L, Hrstka R, Neˇnutl R, Bouchal P. Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. Biochim Biophys Acta. 2017;1865(5):488-98. DOI:10.1016/j.bbapap.2017.02.012

72. Xi W, Rui F, Wang L, Ke D, Ping G, Hui-Zhong Z. Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol. 2009;135(6):837-46. DOI:10.1007/s00432-008-0520-1

73. Nie W, Xu M-D, Gan L, Huang H, Xiu Q, Li B. Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer. Lab Invest. 2014;95(11):56-64. DOI:10.1038/labinvest.2014.124

74. Sun R, Liu Z, Wang L, Li W, Liu J, Ding C, et al. Overexpression of stathmin 1 is resistant to paclitaxel treatment in patients with non-small cell lung cancer. Tumour Biol. 2015;36(9):7195-204. DOI:10.1007/s13277-015-3361-y

75. Yurong L, Biaoxue R, Wei L, Zongjuan M, Hongyang S, Ping F, et al. Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma. Oncotarget. 2017;8(16):26000-12. DOI:10.18632/oncotarget

76. Hemdan T, Lindén M, Lind SB, Namuduri A V, Sjöstedt E, de Stahl TD, et al. The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer. Br J Cancer. 2014;111(6):1810-7. DOI:10.1038/bjc.2014.427

77. Zhang HQ, Guo X, Guo SQ, Wang Q, Chen XQ, Li XN, et al. STMN1 in colon cancer: expression and prognosis in Chinese patients. Eur Rev Med Pharmacol Sci. 2016;20(10):2038-44

78. Lu Y, Liu C, Cheng H, Xu Y, Jiang L, Xu J et al. Stathmin, interacting with N-Kb, promotes tumor growth and predicts poor prognosis of pancreatic cancer. Curr Med Mol. 2014;14(3):328-39.

79. Watanabe A, Arabi K, Yokobori T, Altan B, Ishii N, Tsukagoshi M et al. Stathmin 1 promotes the proliferation and malignant transformation of pancreatic intraductal papillary mucinous neoplasms. Oncol Lett. 2017;13(3):1783-88. DOI:10.3892/ol.2017.5603

80. Hsu HC, Li CF, Lee SW, Wu WR, Chen TJ, Chang K et al. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour Biol. 2014;35(3):2619-29. DOI:10.1007/s13277-013-1345-3

81. Wang F, Xuan XY, Yang X, Cao L, Pang LN, Zhou R, et al. Stathmin 1 is a marker of progression and poor prognosis in esophageal carcinoma. Asian Pac J Cancer Prev. 2014;15(8):3613-8. DOI:10.7314/APJCP.2014.15.8.3613

82. Suzuki S, Yokobori T, Altan B, Hara K, Ozawa D, Tanaka N, et al. High stathmin 1 expression is associated with poor prognosis and chemoradiation resistance in esophageal squamous cell carcinoma. Int J Oncol. 2017;51(3):1345-53. DOI:10.3892/ijo.2017.3899 [Epub ahead of print]

83. Ma HL, Jin SF, Tao WJ, Zhang ML, Zhang ZY. Overexpression of stathmin/oncoprotein 18 correlates with poorer prognosis and interacts with p53 in oral squamous cell carcinoma. J. Cranio-Maxillofacial Surg.2016;44(10):1725–32. DOI:10.1016/j.jcms.2016.07.033

84. Wang J, Yao Y, Ming Y, Shen S, Wu N, Liu J, et al. Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo. Sci Rep. 2016;6:28833. DOI:10.1038/srep28833

85. Tsuchida A, Watanabe S, Inoue M, Asada Y, Maeda M, Takahashi K, et al. Stathmin overexpression in gastric cancer identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res.. 2011;17(10):3368-77. DOI:10.1158/1078-0432.CCR-10-2412

86. He X, Liao Y, Wu X, Tong H, Ke J, et al. Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma. Tumour Biol. 2016;37(7):10441-51. DOI:10.1007/s13277-015-3361-y

87. Serachi FO
88. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, et al. Microarray-based screening for molecular signatures of medulloblastoma revealed STK15 as an independent predictor for survival. Cancer Res. 2004;64(9):3103-11. DOI:10.1158/0008-5472.CAN-03-3968

89. Zanini C, Mandili G, Bertini D, Gerutti F, Bacì D, Leone M, et al. Analysis of different medulloblastoma histotypes by two-dimensional gel and MALDI-TOF. Child’s Nerv Syst 2011;27(12):2077-85. DOI:10.1007/s00381-011-1515-9

90. Liu H, Li Y, Zhou B, Lue L. STMN1 as a candidate gene associated with meningioma progression. Clin Neurol Neurosurg. 2017;159:107-10. DOI:10.1016/j.clineuro.2017.06.003

91. Wang H, Li W, Wang G, Zhang S, Bie L. Overexpression of STMN1 is associated with the prognosis of meningioma patients. Neurosci Lett. 2017;654:1-5. DOI:10.1016/j.neulet.2017.06.020

92. Hanash SM, Strahler JR, Kuck K, Chu EHY, Nichols D. Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem. 1998;273(26):12813-5.

93. Schiappacassi M, Lovisa S, DallaCasa A, Bagnoi M, Lovat F, et al. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med. 2015;3(5):707-22. DOI:10.1002/emmm.201201504

94. Silva VC, Plooster M, Leung JC, Cassimier L. A delay prior to mitotic entry triggers caspase 8-dependent cell death in p53-deficient hela and hct-116 cells. Cell Cycle. 2015;14(7):1070-81. DOI:10.1080/15357163.2015.1007781

95. Ma HL, Jin SF, Ju WT, Fu Y, Tu YY, Wang LZ, et al. Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):109. DOI:10.1186/s13046-017-0575-4

96. Liu J, Cao J, Zhao X. miR-221 facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human bladder cancer cells by targeting STMN1. BMC Urol. 2015;15:36. DOI:10.1186/s12894-015-0028-3

97. Vetter NS, Kolb EA, Mills CC, Sampson VB. The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis. Mol Cancer Res. 2015;13(7):953-64. DOI:10.1158/1541-7786.MCR-15-0372

98. Verma NK, Dourat J, Davies AM, Long A, Liu WQ, Garbay C, et al. p53-mediated negative regulation of stathmin/Op18 expression is associated with G2/M cell-cycle arrest. Int J Cancer. 2000;88(5):685-91. DOI:10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z

99. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C et al. Delay prior to mitotic entry triggers caspase 8-dependent cell death in p53 deficient hela and hct-116 cells. Cell Cycle. 2015;14(7):1070-81. DOI:10.1080/15357163.2015.1007781

100. Fang L, Min L, Lin Y, Ping G, Rui W, Ying Z, et al. Downregulation of stathmin expression is mediated directly by Egr1 and associated with p53 activity in lung cancer cell line A549. Cell Signal. 2010;22(1):166-73. DOI:10.1016/j.cellsig.2009.09.030

101. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006;209(4):549-58. DOI:10.1002/path.2011

102. Alli E, Yang J-M, Hatt WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007;26(7):1003-12. DOI:10.1038/sj.onc.1209664

103. Sonago M, Schiappacassi M, Lovisa S, DallaCasa A, Bagnoi M, Lovat F, et al. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med. 2015;3(5):707-22. DOI:10.1002/emmm.201201504

104. Christie JM, Plooster M, Leung JC, Cassimier L. A delay prior to mitotic entry triggers caspase 8-dependent cell death in p53-deficient hela and hct-116 cells. Cell Cycle. 2015;14(7):1070-81. DOI:10.1080/15357163.2015.1007781

105. Ma HL, Jin SF, Wu T, Fu Y, Tu YY, Wang LZ, et al. Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):109. DOI:10.1186/s13046-017-0575-4

106. Liu J, Cao J, Zhao X, miR-221 facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human bladder cancer cells by targeting STMN1. BMC Urol. 2015;15:36. DOI:10.1186/s12894-015-0028-3

107. Vetter NS, Kolb EA, Mills CC, Sampson VB. The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis. Mol Cancer Res. 2015;13(7):953-64. DOI:10.1158/1541-7786.MCR-15-0372

108. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008;135(4):1281-9. DOI:10.1053/j.gastro.2008.04.003

109. Tamakura K, Yoshiie M, Miyajima E, Kano M, Tachikawa E, Stathmin Regulates Hypoxia-Inducible Factor-1α Expression Through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. ISRN Pharmocol. 2013;2013:279593. DOI:10.1155/2013/279593

110. McGroban BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta - Rev Cancer. 2008;1785(2):96-132. DOI:10.1016/j.bcr.2007.10.004

111. Bai T, Yokobori T, Altan B, Ide M, Mochiki E, Yanai M et al. High STMN1 expression in samples of different medulloblastoma histotypes by two-dimensional gel and MALDI-TOF. Child’s Nerv Syst 2011;27(12):2077-85. DOI:10.1007/s00381-011-1515-9

112. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, et al. Microarray-based screening for molecular signatures of medulloblastoma revealed STK15 as an independent predictor for survival. Cancer Res. 2004;64(9):3103-11. DOI:10.1158/0008-5472.CAN-03-3968

113. Zanini C, Mandili G, Bertini D, Gerutti F, Bacì D, Leone M, et al. Analysis of different medulloblastoma histotypes by two-dimensional gel and MALDI-TOF. Child’s Nerv Syst 2011;27(12):2077-85. DOI:10.1007/s00381-011-1515-9

114. Liu H, Li Y, Zhou B, Lue L. STMN1 as a candidate gene associated with meningioma progression. Clin Neurol Neurosurg. 2017;159:107-10. DOI:10.1016/j.clineuro.2017.06.003

115. Wang H, Li W, Wang G, Zhang S, Bie L. Overexpression of STMN1 is associated with the prognosis of meningioma patients. Neurosci Lett. 2017;654:1-5. DOI:10.1016/j.neulet.2017.06.020

116. Hanash SM, Strahler JR, Kuck K, Chu EHY, Nichols D. Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem. 1998;273(26):12813-5.